产品
编 号：F145621
分子式：C25H28N6O
分子量：428.53
分子式：C25H28N6O
分子量：428.53
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
130
In-stock
5mg
260
In-stock
10mg
416
In-stock
50mg
784
In-stock
100mg
1400
In-stock
200mg
1824
In-stock
500mg
2112
In-stock
结构图
CAS No: 138402-11-6
产品详情
生物活性：
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
体内研究：
Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice.Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects.Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II.Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice.Animal Model:C57BL/6 mice
Dosage:50 mg/kg
Administration:oral gavage; 50 mg/kg/d; once daily
Result:Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis.
Animal Model:C57BL/6 mice
Dosage:20 μM
Administration:20 μM; for 3 h
Result:Downregulated renal CCL20, CCL22 and CCL27 concentrations.
体外研究：
Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro.Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro.Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro.
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
体内研究：
Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice.Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects.Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II.Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice.Animal Model:C57BL/6 mice
Dosage:50 mg/kg
Administration:oral gavage; 50 mg/kg/d; once daily
Result:Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis.
Animal Model:C57BL/6 mice
Dosage:20 μM
Administration:20 μM; for 3 h
Result:Downregulated renal CCL20, CCL22 and CCL27 concentrations.
体外研究：
Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro.Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro.Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备